Sika AG: Price increases for a large part of the product portfolio

Sika AG / Price increases for a large part of the product portfolio processed and
transmitted by Hugin AS. The issuer is solely responsible for the content of this
announcement.

Sika announced today a global price increase for various products from its entire
product portfolio. The price increases will become effective immediately or as contracts
allow.

Global price adjustments are necessary due to significantly increased raw material costs
and will be adapted to the regional raw material price situation. Sika’s local sales
representatives will contact customers individually to explain details of the price
increases.

-END-

Sika AG Contact: Rainer Weihofen,
Zugerstrasse 50 Corporate Communications & Investor Relations
CH-6341 Baar, Switzerland Tel.: +41 58 436 68 00
www.sika.com http://www.sika.com/ Fax: +41 58 436 68 50
weihofen.rainer@ch.sika.com mailto:weihofen.rainer@ch.sika.com

Sika AG Corporate Profile
Sika AG, located in Baar, Switzerland, is a globally active company supplying the
specialty chemicals markets. It is a leader in processing materials used in sealing,
bonding, damping, reinforcing and protecting load-bearing structures in construction
(buildings and infrastructure construction) and in industry (vehicle, building component
and equipment production).
Sika’s product lines feature high-quality concrete admixtures, specialty mortars,
sealants and adhesives, damping and reinforcing materials, structural strengthening
systems, industrial flooring as well as roofing and waterproofing systems. Subsidiaries
in more than 70 countries worldwide and approximately 12 000 employees link customers
directly to Sika and ensure the success of all our partners. Sika achieves annual sales
of CHF 4.2 billion. Visit our website at www.sika.com http://www.sika.com/ .

The media release can be downloaded from the following link:

HUG#1431783

Media Release http://hugin.info/100359/R/1431783/378045.pdf

— End of Message —

Sika AG
Zugerstrasse 50 Baar null

WKN: 858573;ISIN: CH0000587979;

P2i Acquires Surface Innovations

ABINGDON, England–(Business Wire)–
P2i Limited, the world leader in liquid repellent nano-coating technology, has
acquired 100 per cent of the share capital of Surface Innovations Ltd, a
UK-based technology company with a wide range of functional nano-coating
patents. The terms of the deal were not disclosed.

The acquisition expands P2i`s product portfolio beyond its market-leading
technologies for liquid repellency, adding “functional” coating technologies
with applications including anti-bacterial resistance, liquid attracting (super
wettable), and many others.

Surface Innovations is a research and development company with 17 patent
families that focus on functional nano-coatings obtained using plasma enhanced
chemical vapor deposition. It was founded in 2001 by Professor Jas Pal Badyal as
a spin-out of Durham University. Professor Badyal will sit on a new Technical
Advisory Panel to provide ongoing scientific advice to P2i, as well as
developing new patents and applications for the company.

The acquisition of Surface Innovations comes as P2i gains commercial traction in
all five of its core markets: Electronics, Lifestyle, Energy and Filtration,
Life Sciences and Military/Institutional. In the past year, P2i has tripled its
employees to 75 and scaled up its operations, which are now located across
Europe, North America and Asia (China, Singapore, Thailand and Indonesia).

Carl Francis, Chief Executive of P2i, said:
“P2i has excelled in commercializing its liquid repellent nano-coating
technology, proving beyond doubt that plasma processing is a viable, cost
effective industrial process. As our customer base expands and their
requirements broaden, the technology we have acquired will enable us to
commercialize new functional coatings that further enhance the performance of
products ranging from consumer electronics to military clothing.

Professor Jas Pal Badyal, previously majority shareholder of Surface
Innovations, commented:
“I`m delighted that my research and patents are now with P2i, which has a proven
capability in commercializing plasma technology. It is the perfect vehicle to
deploy these various technologies into global markets. We have highly
complementary skills sets and this acquisition will see many exciting new
inventions launched into P2i`s primary markets.”

-Ends-

About P2i
P2i is the world leader in liquid repellent nano-coating technology. We make
good products great by applying innovative science. Our revolutionary technology
enables our customers to improve the performance of their products and protect
them from the effects of water and all other liquids. This builds value by
commanding premium prices and/or reducing costs.

P2i Ltd was established in 2004 to commercialize liquid-repellent treatments
developed by the UK`s Ministry of Defence. Now on a commercial scale, P2i`s
patented process has been successfully applied to a wide range of products in a
wide range of markets including lifestyle, electronics, military and
institutional, life sciences, energy and filtration.

P2i
Carl Francis, Chief Executive
or
Dr Stephen Coulson, Chief Technical Officer
+44 (0)1235 833100
or
College Hill
Adrian Duffield, Carl Franklin, Victoria Cross
+44 (0)20 7457 2020
www.p2i.com

Copyright Business Wire 2010

Chip Makers Adopt ASML`s Holistic Lithography to Continue Moore`s Law

SAN FRANCISCO–(Business Wire)–
ASML Holding NV (ASML) (NASDAQ:ASML) (Amsterdam:ASML) today at SEMICON West
announces broad customer adoption of holistic lithography products which
optimize semiconductor scanner performance and provide a faster start to chip
production. 100% of ASML`s leading-edge scanners are now sold with one or more
holistic lithography components. Semiconductor manufacturers face increasingly
smaller margins of error as they shrink chip features. Holistic lithography
provides a way to shrink within these margins to continue Moore`s Law.

Introduced a year ago at SEMICON West 2009 ASML`s holistic lithography suite of
products enable continued shrink and provide customers with higher yield,
sooner. Holistic lithography integrates computational lithography, wafer
lithography and process control to optimize production tolerances and reduce
“time to money” for chip makers. All of our customers have adopted multiple
products from the holistic product portfolio into research & development (R&D)
as well as volume manufacturing. Products like Source Mask Optimization (SMO),
FlexRay, LithoTuner, Baseliner and YieldStar are in use worldwide.

ASML also offers holistic lithography as an integrated package called Eclipse,
which is tailored to a specific customer, node and application, and which
enables chip makers to squeeze every last bit of performance out of the chip
making process and to enter volume production at the earliest possible time. A
significant number of ASML`s advanced customers have adopted an integrated
Eclipse package.

“Most chip makers have found that for current and future process nodes,
independent optimization of process steps is insufficient. The entire litho
process must be integrated and co-optimized for the best performance. Eclipse
extends the capabilities of their hardware and helps them to produce chips with
smaller geometries, “said Bert Koek, senior vice president, applications product
group at ASML. “With detailed knowledge of our scanner characteristics and
interfaces we can work closely with our customers to integrate computational
lithography solutions during R&D, and implement customized improvement targets
during manufacturing.”

Customers who have adopted Eclipse are seeing the results. STMicroelectronics
for example will incorporate Eclipse in conjunction with a TWINSCAN NXT:1950i
scanner for their 28-nanometer (nm) node. The key deliverables of the package
are on-product specifications for both overlay and critical dimension uniformity
(CDU). The 28-nm Eclipse package for ST includes a full range of products from
ASML, including scanner tuning products, immersion scanner application,
stabilization and conditioning; and the ASML applications support to achieve the
specified targets. Preparations for Eclipse at the next node have started with a
feasibility study on 20-nm critical layer printing options.

“To optimize development cycle times and manufacturing solutions for 28-nm and
beyond, ST is working closely with ASML to define targets, processes and design
parameters,” said Joel Hartmann, Technology R&D Group VP and General Manager
Advanced CMOS, Derivatives and eNVM technology, STMicroelectronics, at Crolles,
France. “ASML`s Eclipse packages include application products, custom project
deliverables and application support that enable joint process optimization.”

About Holistic Lithography and Eclipse

The semiconductor industry is driven by shrink that reduces manufacturing cost
and improves device performance. However, as semiconductor feature sizes shrink,
so do process windows – the accuracy tolerances necessary to produce viable
chips – imposing extremely tight requirements on parameters such as overlay and
critical dimension uniformity (CDU). Independent optimization of separate
parameters is no longer sufficient and holistic lithography intelligently
integrates computational lithography, wafer lithography and process control.

During the chip design phase ASML’s holistic lithography uses actual scanner
profiles and tuning capabilities to create a design with the maximum process
window for a given node and application. Once in manufacturing, ASML holistic
lithography optimizes a scanner for a specific pattern or reticle, and monitors
and controls litho-cell overlay and CDU performance over time to continuously
maintain the system centered in the process window. Integrated into the Eclipse
suite of products are:

* FlexRay uses a programmable array of thousands of individually adjustable
micro-mirrors. It can create any pupil shape in a matter of minutes -
eliminating the long cycle time associated with diffractive optical element
(DOE) design and fabrication and thus accelerating ramp to yield for low k1
designs.
* Tachyon SMO co-optimizes and analyzes scanner source and mask design
simultaneously, ensuring an optimized process window from R&D through production
while minimizing pitch and number of exposures per layer.
* BaseLiner enables optimized process windows and higher yields by keeping
scanner performance to a pre-defined baseline condition.
* YieldStar offers a single sensor solution for CD, overlay and sidewall angle
metrology resulting in high-speed, high precision and high-accuracy measurement.

* LithoTuner optimizes the scanner in an application specific manner. By
combining device pattern information and scanner specific characteristics, the
optimum setting for maximum process window and flexibility will be determined.

About ASML

ASML is the world’s leading provider of lithography systems for the
semiconductor industry, manufacturing complex machines that are critical to the
production of integrated circuits or chips. Headquartered in Veldhoven, the
Netherlands, ASML is traded on Euronext Amsterdam and NASDAQ under the symbol
ASML. ASML has more than 6,600 employees (expressed in full time equivalents),
serving chip manufacturers in more than 60 locations in 15 countries. More
information about Eclipse, including a new video is available on our website:
www.asml.com

ASML Holding NV
Media Relations:
Lucas van Grinsven – Corporate Communications
+31 40 268 3949 – Veldhoven, the Netherlands
or
Ryan Young – Corporate Communications
+1-480-383-4733 – Tempe, Arizona, USA
or
Investor Relations:
Craig DeYoung – Investor Relations
+1-480-383-4005 – Tempe, Arizona, USA
or
Franki D`Hoore – Investor Relations
+31 40 268 6494 – Veldhoven, the Netherlands

Copyright Business Wire 2010

Nipro Diagnostics, Inc. Appoints Scott Verner President

FORT LAUDERDALE, Fla.–(Business Wire)–
Nipro Diagnostics, Inc., a leader in diabetes products and a wholly-owned
subsidiary of Nipro Corporation, announced today the appointment of Scott Verner
as President, with responsibility for the Company`s blood glucose monitoring and
insulin pump business in the U.S., effective immediately. Mr. Verner`s
appointment follows on the recent merger announcement between Home Diagnostics,
Inc. and Nipro Diabetes Systems, Inc., which created Nipro Diagnostics, Inc. Mr.
Verner was previously Senior Vice President of Sales & Marketing at Home
Diagnostics and the newly created Nipro Diagnostics.

Luis Candelario, President of Nipro Medical Corporation, commented, “We are
pleased to appoint Scott Verner as President of Nipro Diagnostics. He is a
seasoned healthcare executive with extensive relationships and deep diabetes
industry knowledge. He has already made significant contributions in rebranding
and repositioning Nipro Diagnostics` BGM products, driving adoption of that
product line and improving our sales infrastructure.”

Mr. Candelario added, “The combination of Nipro Diagnostics` blood glucose
monitoring products with the Amigo Insulin Pump provides a substantial platform
to continue building a leading diabetes product company. Scott is a proven
leader and the ideal candidate to leverage this platform and further strengthen
our leadership in the diabetes product market.”

Scott Verner, President of Nipro Diagnostics, Inc., said, “I am excited to
continue making contributions to building Nipro Diagnostics in my new role. Our
product portfolio has further evolved into a comprehensive and competitive
offering, meeting a wide range of unique consumer needs and exceptionally high
standards for both quality and value. We believe those standards will continue
to be the basis of our growth and success over the next several years.”

Mr. Verner joined Home Diagnostics in 2007 as Senior Vice President of Sales &
Marketing, where he was responsible for developing and executing the Company`s
sales and marketing strategy. During his three year tenure, he strengthened the
Company`s sales infrastructure and successfully rebranded and repositioned the
Company`s blood glucose monitoring product line. This included leveraging new
tools to expand the Company`s market reach, broadening the Company`s managed
care relationships, and obtaining Tier 1 or preferred status for the Company`s
products on key managed care formularies.”

Prior to joining Nipro Diagnostics, Mr. Verner was Vice President of Sales at
EyeTel Imaging, a company focused on developing technologies to treat diabetes
and micro-vascular disease. During his tenure at EyeTel Imaging, he was
responsible for the company`s sales, telesales, marketing and national account
and disease management teams. Prior to EyeTel Imaging, Mr. Verner worked for
Allergan, Inc. where he was instrumental in leading the spin-off of Advanced
Medical Optics (AMO). Before Allergan, Mr. Verner spent 12 years at Novartis,
where he held several sales and marketing positions within the company`s medical
device, OTC and pharmaceutical business units.

About Nipro Diagnostics, Inc.

Based in Fort Lauderdale, Florida, Nipro Diagnostics, Inc. is a leading
developer, manufacturer and marketer of diabetes management products. Nipro
Diagnostics offers a portfolio of high-quality blood glucose monitoring products
and systems available throughout the world. Nipro Diagnostics is the exclusive
co-brand supplier of blood glucose monitoring systems for leading pharmacies
including CVS, Rite Aid and Walgreens, as well as distributors such as
AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical.

Nipro Diagnostics, Inc. has previously announced plans to merge with Nipro
Diabetes Systems, Inc. Both companies are wholly-owned by Nipro Corporation, a
multi-billion dollar company headquartered in Osaka, Japan and a world leader in
providing medical products to the healthcare community. Nipro Diabetes Systems,
located in Miramar, Florida, is the manufacturer and marketer of the Amigo
Insulin Pump. The merger of the two companies results in a comprehensive
diabetes monitoring and insulin management product portfolio, which few
companies offer. This portfolio will help to ensure that patients and their
healthcare professionals have easy access to the high-quality diabetes
monitoring and management tools they need to improve quality of life. Both
companies share a vision of making diabetes monitoring and management more
affordable and are already well-positioned in the quality-value segment of their
respective categories.

For more information, please visit www.niprodiagnostics.com.

Photos/Multimedia Gallery Available:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6346892〈=en

For Nipro Diagnostics, Inc.
The Ruth Group
Eric Reiss, 646-536-7032
ereiss@theruthgroup.com

Copyright Business Wire 2010

APP Pharmaceuticals to Market Anastrozole Tablets in the U.S.

SCHAUMBURG, Ill.–(Business Wire)–
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today
that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in
the U.S., after the U.S. Food and Drug Administration granted approval to market
the breast cancer treatment medication to Fresenius Kabi Oncology Limited
(NSE:FKONCO) (BSE:532545). APP Pharmaceuticals and Fresenius Kabi Oncology
Limited are members of the Fresenius Kabi Group of companies. Anastrozole is
therapeutically equivalent to the reference-listed drug Arimidex, which is
currently marketed by the innovator AstraZeneca.

APP will market Anastrozole in 1 mg tablets. According to IMS data, 2009 sales
of the branded product in the United States were approximately $916.8 million,
with approximately 105 million tablets sold annually.

“The approval of Anastrozole further expands APP’s product portfolio in the
strategically important Oncology segment,” said John Ducker, president and chief
executive officer of APP Pharmaceuticals. “We are delighted to be able to offer
this important oral medication to new customers in the retail pharmacy channel.”

About Anastrozole

Anastrozole is approved for the adjuvant treatment of postmenopausal women with
hormone receptor-positive early breast cancer. It is also a first-line treatment
for postmenopausal women with hormone receptor-positive or hormone receptor
unknown locally advanced or metastatic breast cancer. In addition, Anastrozole
is used in the treatment of advanced breast cancer in postmenopausal women with
disease progression following tamoxifen therapy. Patients with estrogen
receptor-negative disease and patients who did not respond to previous tamoxifen
therapy rarely responded to Anastrozole.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that
develops, manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic and critical
care markets. The company offers one of the most comprehensive product
portfolios used in hospitals, long-term care facilities, alternate care sites
and clinics within North America and manufactures a comprehensive range of
dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly
owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on
September 10, 2008. For more information about APP Pharmaceuticals, Inc., please
visit the company`s Web site at www.APPpharma.com.

Fresenius Kabi Oncology Limited

Fresenius Kabi Oncology Limited is one of the leading companies for cancer
research and anti-cancer products. Leveraging the global outreach through
integration with Fresenius Kabi, Fresenius Kabi Oncology Limited is benchmarking
oncology excellence with world class production, state-of-the-art manufacturing
and research & development facilities. Fresenius Kabi Oncology Limited has world
class expertise for the development and manufacturing of active pharmaceutical
ingredients, intermediates and oral & injectable finished dosage forms.

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in
Europe and in its most important countries of Latin America and Asia Pacific.
Fresenius Kabi`s core product range includes infusion solutions, blood volume
substitutes, I.V. drugs and parenteral nutrition, as well as products for
enteral nutrition. Furthermore, the company provides concepts for ambulatory
health care and is focused on managing and providing home therapies. With the
philosophy “caring for life” and a comprehensive product portfolio, the company
aims at improving the quality of life of critically and chronically ill patients
all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million
and an operating profit of EUR 607 million. For more information visit the
company`s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100%
subsidiary of Fresenius SE.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in this news
release include statements regarding our expectations, beliefs, hopes, goals,
intentions, initiatives or strategies, including statements regarding the
demand, supply and distribution of our products. Because these forward-looking
statements involve risks and uncertainties, there are important factors that
could cause actual results to differ materially from those in the
forward-looking statements. Additional relevant information concerning risks are
discussed under the headings “Risk Factors” and “Management`s Discussion and
Analysis of Financial Condition and Results of Operations” in the Fresenius Kabi
Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2009
and other documents the company has filed with the Securities and Exchange
Commission.

The information contained in this news release is as of the date of this
release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any
obligation to update or revise these forward-looking statements to conform the
statement to actual results, new information, developments or changes in the
Company`s expectations.

1 2009 IMS Data

Arimidex is a registered trademark of AstraZeneca.

Investor and Media Inquiries
APP Pharmaceuticals, Inc.
Debra Lynn Ross, ABC
Director, Corporate Communications
(847) 969-8026
dross@apppharma.com

Copyright Business Wire 2010

Komax Holding AG: Bundling resources in Solar

Komax Holding AG / Bundling resources in Solar processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this announcement.

With a view to bundling resources, Komax will in the medium-term be integrating its
thin-film activities into its new plant in York, USA. Up to 45 jobs will be cut in the
coming months at the plant in Rotkreuz, Switzerland. Business is continuing to develop
very well in the crystalline segment, which accounts for around 85 percent of Komax’s
solar business.

The Komax Group is transferring its thin-film business from Rotkreuz to York, USA, where
the Group established a new solar plant in 2009. This means that up to 45 jobs will be
cut in the coming months at the plant in Rotkreuz, Switzerland. In taking this step, the
Group is responding to the continuing decline in the thin-film solar market and is
integrating this activity into its York site.

In contrast to the thin-film segment, the crystalline business, which accounts for some
85 percent of Komax’s solar sales, has performed very well. In this area, Komax is
benefitting from its strong market position and from major orders from Asia.

Brief profile of the Komax Group: global leader in wire-processing, strong focus on
photovoltaics and medical technology

Komax is the world leader in the wire-processing market (crimp-to-crimp machines), with
a market share of around 40 percent. In addition, the Komax portfolio of products and
services ranges from wirecutting and -stripping machines all the way to systems for the
fully-automated manufacture of complete wire harnesses.

In the solar field, Komax is a worldwide supplier of machines for the production of
crystalline and thin-film modules. Continuous innovation has enabled Komax to expand its
product portfolio significantly in recent years. Today, the company covers the entire
spectrum, from individual processes such as stringing through to integration of entire
production lines. Its aim is to expand its global leadership in stringing to the other
areas of its product portfolio.

In the medical technology sector, Komax produces, for example, machine systems for
manufacturing inhalers and insulin delivery or injection systems. In this field too,
Komax is among the world’s leading suppliers.

Contact:

Komax Holding AG Tel +41 41 455 06 16
Dominik Slappnig Fax +41 41 450 10 24
Head of Investor Relations & Corporate Communications dominik.slappnig@komaxgroup.com mailto:dominik.slappnig@komaxgroup.com
www.komaxgroup.com http://www.komaxgroup.com/

The media release can be downloaded from the following link:

HUG#1427130

Media release (PDF) http://hugin.info/100418/R/1427130/374788.pdf

— End of Message —

Komax Holding AG
Industriestrasse 6 Dierikon-LU Switzerland

WKN: 1070215 ;ISIN: CH0010702154;

Cegedim Strategic Data (CSD) Launches New Website

PARIS, Jun 24 (MARKET WIRE) —
Cegedim Strategic Data, leading provider of integrated healthcare
research, is pleased to announce the launch of its new website
www.cegedimstrategicdata.com. The new redesigned website is more dynamic
and easy to use.

The website features a public section open to all online visitors and a
dedicated client section. This site was updated to facilitate the
delivery of reports and studies to pharmaceutical companies via online
access.

This site now has a dedicated client area, where each pharmaceutical
company has direct online access to their completed studies and reports
which have been uploaded by CSD.

Pharmaceutical companies also have access to a specific CSD Promotion
application (Verbatim) where they can make a query and download directly
a report with the messages physicians recall during the Medical
Representative’s visit. This report assists them to determine if their
marketing strategy is having the desired impact.

Other new features include increased interactivity, a regularly updated
news section with the latest CSD product developments, improved client
Newsletter section, and a career section covering all of CSD’s branches
worldwide.

Bruno Sarfati, CSD CEO declared: “This new website gives a comprehensive
overview of CSD’s unique product portfolio, and provides clients with a
secure service to access CSD’s research solutions.”

About Cegedim Strategic Data:
CSD is a leading Market Research company
dedicated to the healthcare industry and operating in more than 60
countries.

With over 36 years experience in the Pharmaceutical industry, CSD offers
a comprehensive range of market research services and solutions to its
customers, which include more than 50 global and 500 local Pharmaceutical
companies. CSD integrates primary and secondary analyses with its medical
expertise to meet its customer’s research needs.

To learn more, please visit our website: www.cegedimstrategicdata.com

About Cegedim: Founded in 1969, Cegedim is a global technology and
services company specializing in the healthcare field. Cegedim supplies
services, technological tools, specialized software, data flow management
services and databases. Its offerings are targeted notably at healthcare
industries, life sciences companies, healthcare professionals and
insurance companies. The world leader in life sciences CRM, Cegedim is
also one of the leading suppliers of strategic healthcare industry data.
Cegedim employs 8,600 people in more than 80 countries and generated
revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris
(EURONEXT: CGM). To learn more, please visit: www.cegedim.com

Media inquiries

CEGEDIM STRATEGIC DATA
Pauline Fahey
Global Marketing and Communications
Tel: + 33 (0)1 49 09 83 87
pauline.fahey@cegedim.com

CEGEDIM
Aude Balleydier
Media Relations
Tel: + 33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr

Copyright 2010, Market Wire, All rights reserved.

Research and Markets: Global SaaS-Based Customer Relationship Management Market 2009-2013

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/2df54f/global_saasbased) has
announced the addition of the “Global SaaS-based CRM Market 2009-2013″ report to
their offering.

SaaS (Software-as-a-Service)-based Customer Relationship Management (CRM) is an
on-demand deployment of CRM software, where the user can access the software
through license or lease as a Web-based service. It provides an alternative to
implementation or maintaining CRM software.

The SaaS-based CRM is increasingly becoming popular as resources are maintained
by a service provider. Further, SaaS-based CRM provides flexible, low-cost
business model to enable its customers focus more on their core business.
Moreover, the businesses can easily meet the fluctuating demands through this
model. Additionally, the SaaS-based CRM service provider gives customers
network-based access to a single copy of CRM application, which is created
specifically for SaaS distribution. Thus, it eliminates the need for time
consuming patches and updates in the software.

The tough economic conditions have resulted in the growth of the SaaS-based
marketing model. This is because it provides the companies with cost-effective
option of accessing a software-as-a-service instead of implementing the entire
package software. Thus, the companies are adopting new technologies such as
SaaS-based CRM that can substantially reduce the cost.

Presently, the credit crunch and small & medium businesses are opting for
SaaS-based CRM as a cost effective alternative by making installment based
payments. Moreover, most of the IT companies are channelizing their product
portfolio and introducing new service offerings (like social networking services
through the SaaS-based CRM). Further, the increasing use of Web-based computing
and popularity of Web-based applications have fueled the growth of SaaS-based
CRM. Furthermore, the companies are exploring new mediums to enhance the
customer experience through the adoption of SaaS-based CRM.

This report highlights scope of the SaaS-based CRM market, along with trends,
drivers, growth inhibitors and a few major vendors in the market.

Key Topics Covered:

1. Introduction

2. Market Size and Forecast

3. Geographic Segmentation

3.1. Market Size in Americas

3.2. Market Size in EMEA

3.3. Market Size in APAC

4. Market Trends in SaaS-based CRM

5. Market Drivers in SaaS-based CRM

6. Market Challenges in SaaS-based CRM

7. Vendors

For more information visit

http://www.researchandmarkets.com/research/2df54f/global_saasbased

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

Immunomedics to Present at Upcoming Investor Conferences

MORRIS PLAINS, N.J., June 4, 2010 (GLOBE NEWSWIRE) — Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal
antibodies to treat cancer and other serious diseases, today announced that
Cynthia L. Sullivan, President and Chief Executive Officer, will be presenting
at the Jefferies 2010 Global Life Sciences Conference, scheduled for Wednesday,
June 9 at 8:30 am in New York, NY.

In addition, Gerard G. Gorman, Senior Vice President of Finance and Business
Development, and Chief Financial Officer, will present at the Wells Fargo
Securities 2010 Healthcare Conference on Thursday, June 24th at 2:30 pm at The
InterContinental Boston.

Both presentations, which can be accessed at
www.immunomedics.com/1aboutus/present.pdf, will provide a corporate overview,
including comments on the Company’s product portfolio.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal, antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases. We have developed a
number of advanced proprietary technologies that allow us to create humanized
antibodies that can be used either alone in unlabeled or “naked” form, or
conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case
to create highly targeted agents. Using these technologies, we have built a
pipeline of therapeutic product candidates that utilize several different
mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals,
Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for
making fusion proteins and multifunctional antibodies, and a new method of
delivering imaging and therapeutic agents selectively to disease, especially
different solid cancers (colorectal, lung, pancreas, etc.), by proprietary,
antibody-based, pretargeting methods. We believe that our portfolio of
intellectual property, which includes approximately 149 patents issued in the
United States and more than 375 other patents issued worldwide, protects our
product candidates and technologies. For additional information on us, please
visit our website at www.immunomedics.com. The information on our website does
not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking
statements made pursuant to the Private Securities Litigation Reform Act of
1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, and capital raising
activities, involve significant risks and uncertainties and actual results could
differ materially from those expressed or implied herein. Factors that could
cause such differences include, but are not limited to, risks associated with
new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on our licensing partners for the further
development of epratuzumab for autoimmune indications and veltuzumab for
non-cancer indications, competitive risks to marketed products and availability
of required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company’s filings with the Securities and
Exchange Commission. The Company is not under any obligation, and the Company
expressly disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events or otherwise.

CONTACT: Immunomedics, Inc.
Dr. Chau Cheng, Associate Director, Investor Relations &
Business Analysis
(973) 605-8200, extension 123
ccheng@immunomedics.com

Virage Logic`s Executive Chairman to Present at the UBS Global Technology and Services Conference

FREMONT, Calif.–(Business Wire)–
Virage Logic Corporation (Nasdaq:VIRL), the semiconductor industry’s trusted IP
partner, announced today J. Daniel McCranie, Executive Chairman, will be
presenting at the UBS Global Technology and Services Conference on Tuesday, June
8th at 1:30 pm EDT. The conference will be held at the Crowne Plaza Times Square
in New York City.

A live webcast and replay of Virage Logic`s presentation at the UBS conference
will be available at:
http://cc.talkpoint.com/ubsx001/060810a_cy/?entity=101_QKO014H or on the
investor relations page of the Virage Logic web site.

About Virage Logic

Virage Logic is a leading provider of semiconductor intellectual property (IP)
for the design of complex integrated circuits. The company’s highly
differentiated product portfolio includes processor solutions, interface IP
solutions, embedded SRAMs and NVMs, embedded test and yield optimization
solutions, logic libraries, and memory development software. As the
semiconductor industry’s trusted IP partner, more than 400 foundry, IDM and
fabless customers rely on Virage Logic to achieve higher performance, lower
power, higher density and optimal yield, as well as shorten time-to-market and
time-to-volume. For further information, visit http://www.viragelogic.com.

All trademarks are the property of their respective owners and are protected
herein.

Virage Logic Corporation
Brian Sereda, 510-360-8017
Chief Financial Officer
brian.sereda@viragelogic.com

Copyright Business Wire 2010

General Mills 2010 Corporate Social Responsibility Report Now Available

Highlights progress in areas of health, community and environment
MINNEAPOLIS–(Business Wire)–
General Mills` 2010 Corporate Social Responsibility report highlights new and
long-standing achievements in the areas of health, community and environment.
The report is available for download at GeneralMills.com/csr.

The new report highlights:

* Improvements of nearly 50 percent in the nutrition profile of its products
since 2005.
* Contributions of nearly $91 million in philanthropic giving — up 4.3 percent
over fiscal 2008.
* New and innovative ways the company is trimming waste and reducing its
environmental footprint.

“To truly live our mission of Nourishing Lives, we must go far beyond achieving
financial success,” said Ken Powell, chairman, chief executive officer, General
Mills. “It includes Nourishing Communities around the world by volunteering and
giving to worthwhile causes, and Nourishing the Future by helping to preserve
and protect the environment for generations to come.”

This is the 40th year the company has published the report, which has promoted
various aspects over the years. The 2010 CSR report is divided into three
sections: health, community and environment, and includes several videos
inserted throughout the electronic document. The following is a brief overview
of what`s inside the report.

Health Improvements

General Mills has improved the nutrition profile by nearly 50 percent of its
product portfolio through the health metric initiative launched in 2005. Its
biggest gains have been through adding whole grains to products such as cereal,
although focus has also been placed on adding vitamins, fiber and calcium, as
well as reducing fat, sodium and sugar.

“Our organization is fully committed to improving the nutritional profile of our
broad range of products,” said Peter Erickson, senior vice president,
Innovation, Technology and Quality at General Mills. “Each time we touch a
product – new or existing – we think about what big or small steps can be made.
The progress indicated by our health metrics is a reflection of our success to
date.”

The company has been reducing sodium in its products for years, but it announced
in the 2010 CSR report that it will accelerate its sodium reduction strategy to
target an average 20 percent sodium reduction in 600 SKUs (stock-keeping units)
by 2015. Last December, the company also announced a commitment to reduce the
sugar in its cereals advertised to kids to single-digit levels of grams per
serving.

The report also explains that the company`s Big G cereals deliver almost 35
million whole grain servings per day – a 40 percent increase in Big G`s whole
grain serving contribution from 2005.

Community Commitments

General Mills operates in more than 100 countries around the world and is
committed to Nourishing Communities. General Mills` giving increased to nearly
$91 million – up 4.3 percent over fiscal 2008. Since 2000, General Mills has
contributed about 5 percent of its pretax profits to a wide variety of causes.

The largest share of these contributions — $53.6 million in fiscal 2009 — is
from what the company calls “brand philanthropy” – programs directly linked to
its businesses, such as Box Tops for Education, which raises money for K-8
education, and YoplaitSave Lids to Save Lives, which raises money for breast
cancer research and education.

General Mills` philanthropic efforts in Africa also continue to expand. More
than 5,000 people became members since last fall`s launch of Join My Village,
General Mills` online initiative to help empower women and girls in 75 villages
in Malawi. Women and girls grow and prepare most of the food in the region.

“We`re lending our technical expertise, too. Over the past two years, more than
300 General Mills researchers and scientists have logged more than 20,000
volunteer hours to help solve technical issues at several African
food-processing facilities,” said Chris Shea, senior vice president of General
Mills, and president of the General Mills Foundation.

Closer to home, General Mills has received praise for its workplace culture. The
company was named one of the “100 Best Companies to Work For” by Fortune
magazine as well as ranked No. 3 by the magazine for “Global Top Companies for
Leaders.”

Environmental Performance

The company is making progress on its five-year goals to reduce its
environmental impact. The solid waste generation rate was reduced by 24.5
percent since 2005 – far surpassing our goal of 15 percent. Water usage was
reduced by 2.2 percent since 2005, which is nearly halfway to achieving a 5
percent reduction by 2011. Progress on reducing energy consumption and
greenhouse gas emission rates has been 2.4 percent and 2.3 percent,
respectively. The company expects the systems now in place to produce greater
reductions in the future.

Leftover oat hulls from making Cheerios are being used to fuel a power plant
near Minneapolis that has the capacity to generate enough electricity to power
30,000 homes. Soon oat hulls will also be used to generate electricity for the
company`s mill in Fridley, Minn.

Betty Crocker Warm Delights desserts now feature new bowls that contain 40
percent less plastic, perform better in the microwave and cost less to make.
It`s an additional example of measures taken by General Mills that have helped
reduce its solid waste generation rate by 24.5 percent since 2005, far
surpassing its goal of 15 percent.

General Mills` San Adrian facility in Spain switched to an electricity provider
that uses only natural and renewable sources such as wind power. The move saves
$175,000 per year in costs and reduces carbon dioxide emissions by more than
6,000 tons. The San Adrian plant now gets 100 percent of its electricity – and a
third of its energy overall – from renewable sources.

“We recognize that we face many challenges ahead, and are working to develop and
extend a new set of environmental goals. But we sincerely believe that we can
`do well` for our shareholders, while continuing to `do good` for our customers,
our communities and our planet,” said Powell.

Recent Recognition

General Mills has received many honors recognizing the company`s strong
commitment to corporate responsibility, including: Newsweek ranks General Mills
as one of the “100 Greenest Companies in America”; Corporate Responsibility
magazine`s “100 Best Corporate Citizens” ranked the company in the top 10; and
for the third year in a row, Ethisphere Institute listed the company as one of
the “World`s Most Ethical Companies.” Fortune magazine also included General
Mills in its list of the top 50 “World`s Most Admired” companies for two years
running.

About General Mills

One of the world’s leading food companies, General Mills operates in more than
100 countries and markets more than 100 consumer brands, including Cheerios,
Häagen-Dazs, Nature Valley, Betty Crocker, Pillsbury, Green Giant, Old El Paso,
Progresso, Cascadian Farm, Muir Glen, and more. Headquartered in Minneapolis,
Minnesota, USA, General Mills had fiscal 2009 global net sales of US$15.9
billion, including the company`s $1.2 billion proportionate share of joint
venture net sales.

General Mills
Heidi Geller, 763-764-6364

Copyright Business Wire 2010

Bedford Funding/Peopleclick Transaction Awarded “Deal of the Year” by Association for Corporate Growth

RALEIGH, NC, Apr 14 (MARKET WIRE) —
In a ceremony held earlier this morning, executives from Peopleclick
Authoria and Bedford Funding received the “Deal of the Year” Award from
the Association for Corporate Growth in Raleigh Durham, NC. The companies
were recognized for the January transaction in which Bedford Funding, a
$400 million private equity firm specializing in investments in the
software and IT sector, acquired Peopleclick for $100 million.

Sixty equity funds representing $250 billion in capital attended the
conference and panel discussion featuring executives from Bedford Funding
and Peopleclick Authoria. In this morning’s discussion, moderated by
Robert E. Duggins, Partner, Smith, Anderson, Blount, Dorsett, Mitchell &
Jernigan, L.L.P., Jon Salon, Managing Director of Bedford Funding and Ron
Kupferman, previous Chairman and CEO of Peopleclick and current Vice
Chair of Peopleclick Authoria, highlighted key elements of the
transaction, opportunities within the Human Capital Management
marketplace and the strength of the Peopleclick product portfolio and the
Peopleclick Authoria combination.

Following the transaction, Bedford Funding immediately combined
Peopleclick’s operations with Authoria, an existing Bedford Funding
portfolio company to create the industry’s first provider of fully
integrated best-of-breed Talent Management solutions. The combination of
these two leading independent brands, now operating under the Peopleclick
Authoria name, currently serves nearly 60 percent of the Fortune 100 and
brings an unmatched suite of Talent Management software, services and
consulting solutions to enterprise businesses around the world.

About Peopleclick Authoria
Peopleclick Authoria is transforming Talent
Management through best-of-breed technology and expertise. With a deep
focus on business intelligence and analytics, the company’s technology
gives clients the actionable insight required to make strategic decisions
that drive better business results. Nearly 60 percent of the Fortune 100
use Peopleclick Authoria Talent Acquisition, Talent Management and
Workforce Compliance and Diversity solutions to manage salaried, hourly
and contingent labor across their organization. These solutions manage
the entire talent lifecycle from recruiting to onboarding and through the
ongoing management of each individual’s career while helping
organizations measure, analyze and empower their existing workforce. Both
founded separately in 1997, the two human capital management companies
joined together in 2010 to form Peopleclick Authoria. The Company’s
solutions currently support more than 2,400 organizations ranging in size
from large, global corporations to small and medium-sized businesses in
more than 214 countries and territories around the world.

For more information, please contact:

Alys Scott
Vice President, Corporate Communications
Peopleclick Authoria
Email Contact

Maura Landry
Senior Account Manager for Peopleclick Authoria
SHIFT Communications
(617) 779-1829
Email Contact

Copyright 2010, Market Wire, All rights reserved.

Zoot Awarded Contract for Automating Loan Origination at Thrivent Financial Bank

Solution Helps Bank Expand Customer Base, Increase Efficiency, Reduce Costs
BOZEMAN, Mont.–(Business Wire)–
Zoot, a leading provider of advanced instant credit decisioning and loan
origination solutions, announced the successful deployment of the company`s
zOriginateSMloan origination solutionat Thrivent Financial Bank* at the 2010
TowerGroup Annual Financial Services Strategy & Technology Conference &
Exhibition. The Zoot platform provides an operationally efficient loan
underwriting process for the bank and its clients.

“We needed the ability to integrate with multiple vendors to support our
multi-state lending product portfolio,” said Wendy Clausz, SVP of Bank
Operations of Thrivent Financial Bank. “zOriginate provides real-time
information to our staff enabling them to present the best loan options more
quickly, creating an even more positive client experience while reducing loan
processing time and costs.”

zOriginate facilitates the entire origination process from beginning to end
giving business users direct control over decisioning and workflow through one
interface and one tool. The solution increases the efficiency of loan
origination by automating as much as possible, seamlessly integrating between
automated and manual processes when necessary. Zoot`s zOriginate loan
origination solution contains a vendor network component that features
connections to any data and service provider an institution requires. Zoot`s
vendor network has established connections to third-party data and service
providers through a single interface, eliminating the challenge and costs of
connecting to and maintaining each vendor individually. “zOriginate was designed
to simplify the loan origination process for our clients and their customers.
Our solutions quickly and easily integrate into a variety of systems and network
configurations,” said Dennis Dixon, president of Zoot Enterprises. “Zoot`s tools
and services give our clients the control and flexibility to implement their
best business practices and address specific points of pain instead of forcing
them to adapt their processes to fit the parameters of the solution.”

Visit Zoot`s website to learn more about zOriginate loan origination solution or
complete an information request form.

About Zoot

Bozeman, Mont.-based Zoot provides comprehensive credit decisioning, loan
origination and credit risk management solutions to enable clients` unique
business objectives, leading to long-term relationships with top U.S. banks.
Zoot`s rapid, high-volume processing environment has the capacity to process
billions of transactions per year. Visit http://www.zootweb.com or call
406-556-7555 for more information.

*Thrivent Financial Bank is a Member of the FDIC and an Equal Housing Lender.

For Zoot Enterprises
Andrew McCaskill, 678-781-7210
or
Anna Stanley, 251-990-3559
or
Zoot Enterprises
Public Relations
Karen Gordon, 406-556-8977

Copyright Business Wire 2010

OSI Pharmaceuticals to Announce First Quarter 2010 Financial Results on April 22, 2010

Conference Call and Webcast to Follow -
MELVILLE, N.Y.–(Business Wire)–
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its first quarter
2010 financial results will be released on April 22, 2010, after the markets
close. Following the announcement, OSI`s management will host a live conference
call and webcast at 5:00 p.m. Eastern Time to review the Company`s financial
results, product portfolio and business developments.

To access the live webcast or the archive via the Internet, log on to
www.osip.com. Please connect to the Company’s website at least 15 minutes prior
to the conference call to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call 1-888-378-4350
(U.S.) or 1-719-457-2710 (international) to listen to the call. The conference
ID number for the live call is 5184529. Telephone replay is available
approximately two hours after the call. To access the replay, please call
1-888-203-1112 (U.S.) or 1-719-457-0820 (international). The conference ID
number for the replay is 5184529.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by
discovering, developing and commercializing high-quality, novel and
differentiated targeted medicines designed to extend life and improve the
quality of life for patients with cancer and diabetes/obesity. For additional
information about OSI, please visit http://www.osip.com.

OSI Pharmaceuticals, Inc.
Kathy Galante (investors/media)
Senior Director
631-962-2043
or
Kim Wittig (media)
Director
631-962-2135
or
Media:
Joele Frank, Wilkinson Brimmer Katcher
Joele Frank/Andy Brimmer/Eric Brielmann
212-355-4449
or
Investors:
Burns McClellan
Lisa Burns
212-213-0006

Copyright Business Wire 2010

BIOTRONIK adds New “Reocor” External Pacemaker to its High-Quality Product Portfolio

Reocor combines intuitive design with unprecedented longevity
BERLIN–(Business Wire)–
BIOTRONIK SE & Co. KG today announced the European launch after receiving CE
Mark approval for its new Reocorexternal pacemakers, available in two models for
dual and single chamber pacing therapy.

Quality based on 25 years of experience
BIOTRONIK continues to enrich its high quality product portfolio with the launch
of the new external pacemakers. Reocor offers complete reliability in
emergencies and temporary patient care, setting a new quality standard for
external pacing therapy.

Reocor – Intuitive design for safe usage in daily practice
The new Reocor has an intuitive design for simplified usage and extended
longevity that increases reliability and reduces costs over time. Simplified
usage is achieved by the function dials displaying selectable parameter values
and visualizing programmed settings at a glance. Thus, easy handling is
guaranteed without any specific training requirements. Extended battery service
times of up to 25 days for permanent pacing therapy, supplemented with a backup
power supply during battery replacement, ensure patient safety and longer
continuous usage in daily practice. Reocor has also been enhanced to accommodate
high pacing outputs and high pacing rates being especially important for
pediatric care. Therefore Reocor effectively delivers individual solutions for a
broad range of patients.

“Reocor represents the first in a series of advanced new external devices that
BIOTRONIK will launch. In 2010 we will be offering a new external pacemaker, a
new pacing system analyzer and a completely new programmer which demonstrates
our commitment to develop the highest quality and the most complete CRM product
portfolio. Reocor represents the ultimate promise of reliability to our
customers with clear advantages in its ease of use, unsurpassed longevity, and
convenient mobility in a small and lightweight housing,” stated Marlou Janssen,
Vice President, Global Marketing and Sales, Cardiac Rhythm Management,
BIOTRONIK.

About BIOTRONIK SE & Co. KG
As one of the world`s leading manufacturers of cardiovascular medical devices,
with several million devices implanted, BIOTRONIK is represented in over 100
countries by its global workforce of more than 5,100 employees. Known for having
its finger on the pulse of the medical community, BIOTRONIK assesses the
challenges physicians face, and provides the best solutions for all phases of
patient care, ranging from diagnosis to treatment to patient management.
Quality, innovation and reliability define BIOTRONIK and its growing success,
and deliver confidence and peace of mind to physicians and their patients
worldwide.

More information: www.biotronik.com

Upon publication, please provide us with a copy.

BIOTRONIK SE & Co. KG
Sandy Hathaway, Senior Director, Corporate Communications
Tel. + 49 (0) 30 68905 1602
Email: sandy.hathaway@biotronik.com

Copyright Business Wire 2010

Biotage AB (publ) Publishes Its 2009 Annual Report

STOCKHOLM–(Business Wire)–
Regulatory News:

Biotage (STO:BIOTA) is today publishing its 2009 annual report.

The company generated net sales of 394.1 MSEK (385.3 MSEK).

The operating result amounted to – 10.1 MSEK (27.2 MSEK) and total profit after
tax for the year of 13.5 MSEK (299.1 MSEK).

Total profit per share of 0.15 SEK (3.38 SEK).

Financial Goals 2010 and onwards

Following the sale of the Biosystems business area in 2008, Biotage has
formulated new long-term financial goals for its operations. An extensive
restructuring program was also implemented in 2009 within the remaining
operations. In order to achieve the new long-term goals, a continued change
process is required as well as a return to a more normal market climate than
that experienced in 2009. The market for instruments was particularly weak
during the year. Long-term and stable profitability requires a critical mass
within each customer segment and having a sufficiently broad product portfolio.
This critical mass can be attained through a combination of organic growth and
strategic acquisitions. The Company believes that the new long-term goals
presented below can be achieved by 2012.

* Organic growth of at least 10 percent
* Increase of the gross margin by 1-2 percentage points per annum, with the goal
of achieving a gross margin exceeding 60 percent
* EBIT margin of at least 10 percent

The full report is available at: www.biotage.com

The information in this press release is such that Biotage AB is required to
disclose under the Swedish Securities Market Act and/or the Swedish Financial
Instruments Trading Act. It was released for publication at 8am (CET) on 8 April
2010.

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical
and medicinal chemistry. The customers include the world`s top pharma and
biotech companies, as well as leading academic institutes. The company is
headquartered in Uppsala, Sweden, and has offices in the United States, United
Kingdom and Japan. Biotage has 245 employees and had sales of SEK 394,1m in
2009. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website:
www.biotage.com

This information was brought to you by Cision http://www.cisionwire.com

Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84
torben.jorgensen@biotage.com

Copyright Business Wire 2010

Nuance Launches Dragon Dictation for iPad

Optimized for iPad, Free New Dictation App Lets iPad Users Simply Speak Text for
Emails, Documents, Status Updates, Notes, and More
BURLINGTON, Mass.–(Business Wire)–
Nuance Communications, Inc. (NASDAQ: NUAN) today announced the availability of
Dragon Dictation for iPad on the Apple App Store. With the newest addition to
the Dragon Dictation family, iPad users can take advantage of the power of
Dragon NaturallySpeaking to speak their email messages. The app also includes a
new Dragon Dictation Notes feature that lets users speak and save drafts of
documents, emails, to-do lists, social media status updates, and more.

“Dragon Dictation has proven to be a must-have app for iPhone and iPod touch, so
it made sense to immediately extend those benefits to iPad,” said Michael
Thompson, senior vice president and general manager, Nuance Mobile. “The iPad is
a unique and remarkable device, and with the Dragon Dictation App users can
experience added flexibility and convenience as they quickly convert speech into
text.”

The Dragon Dictation App can turn spoken words into text up to five times faster
than typing. This latest edition is designed specifically for iPad and
capitalizes on the large screen size to include the new Dragon Dictation Notes
feature, where dictated text can be easily saved, viewed and managed. The app
can also be used in either portrait or landscape mode.

The Dragon Dictation App for iPad is available for free for a limited time from
the App Store on iPad or at www.itunes.com/appstore/.

To learn more, visit www.dragonmobileapps.com. Also be sure to follow Nuance on
Twitter @DragonTweets and @NuanceMobile, and become a Fan of Dragon Mobile Apps
on Facebook.

Dragon Dictation is part of the Dragon Mobile Apps family that brings the power
of Dragon NaturallySpeaking to iPhone, iPod Touch and now iPad. Nuance`s broad
product portfolio of speech and predictive text and search solutions are trusted
by the world`s leading manufacturers and mobile operators, and are found in
billions of phones and millions of automobiles and consumer electronic devices -
making them among the most pervasive mobile solutions on the market today.

About Nuance Communications, Inc.

Nuance is a leading provider of speech and imaging solutions for businesses and
consumers around the world. Its technologies, applications and services make the
user experience more compelling by transforming the way people interact with
information and how they create, share and use documents. Every day, millions of
users and thousands of businesses experience Nuance`s proven applications and
professional services. For more information, please visit: nuance.com.

Nuance, NaturallySpeaking, Dragon, Dragon Dictation Notes and the Nuance logo
are trademarks or registered trademarks of Nuance Communications, Inc. or its
subsidiaries in the United States of America and/or other countries. All other
company names or product names may be the trademarks of their respective owners.

The statements in this press release, relating to future plans or future events
or services, are forward-looking statements which are subject to specific risks
and uncertainties.There are a number of factors which could cause actual events
or results to differ materially from those indicated in such forward looking
statements, including fluctuations in demand for the Nuance products, the
relationship with thepartner and the continued development of Nuance
products.The reader is warned not to rely on these forward-looking statements
without reservation, since these are simply reflections of the current
situation.Nuance disclaims any obligation to update any forward-looking
statements as a result of developments occurring after the date of this
document.

Photos/Multimedia Gallery Available:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6236650〈=en

Nuance Contact:
Nuance Communications
Rebecca Paquette, 781-565-5264
rebecca.paquette@nuance.com
or
GRC for Nuance Communications
Valerie Christopherson, 949-608-0276
nuancemobile@globalresultspr.com
or
International
Nuance Communications International
Vanessa Richter, +32-9-239 80 31
vanessa.richter@nuance.com

Copyright Business Wire 2010

Yahama Fazer – Yahama India – Yahama Fazer 250 – Yahama Fazer 250 cc – Yamaha Fazer launched in India

Yahama Fazer – Yahama India – Yahama Fazer 250 – Yahama Fazer 250 cc – Yamaha Fazer launched in India

Yahama Fazer - Yahama India - Yahama Fazer 250 - Yahama Fazer 250 cc - Yamaha Fazer launched in India After huge success of Yamaha FZ16, Yamaha YZF R15 and Yamaha FZS, Yamaha launched its global model Yamaha Fazer in Indian market.

Yamaha Fazer is the third bike from Yamaha product portfolio that is build on its popular model Yamaha FZ16 platform. Yamaha Fazer is equipped with a 153cc engine that produces 14PS of maximum power at 7500rpm and 14Nm of maximum torque at 6500rpm.

The Yamaha Fazer comes with the bigger rear tyre of 140-60 with 17″ alloy wheels. Yamaha Fazer is available at Rs 72,000 (as ex-showroom prices in New Delhi).

Yamaha Fazer is available with four exciting colours that are blue, black, red and orange.

TANDBERG technology breakthrough shatters the barrier of proprietary telepresence

Bangalore, Apr 30 (ANI/Business Wire India): TANDBERG announced ts Telepresence T3 is the first and only immersive telepresence solution that maintains the multi-screen, high-definition telepresence experience when calling out to a third-party telepresence system.

This new functionality is meeting the growing demands of organizations that require all video systems to fully interoperate, putting an end to siloed communication.

“Organizations are turning to telepresence solutions now more than ever for the fast return on investment from reduced travel and increased productivity. However, as unified communications become more and more important, enterprises can9t afford to invest in solutions that cannot work together,” said Dominic Dodd, Global Program Director, Unified Communications and Collaboration, Frost and Sullivan.

“By enabling telepresence systems to interoperate TANDBERG has upped the ante by creating a standard that all telepresence providers will have to live up to if they want to be included in future purchasing decisions,” added Dodd.

Recognized for outstanding design, the Telepresence T3 provides the best telepresence experience in the industry.

It is interoperable with the TANDBERG product portfolio, Microsoft Office Communications Server, and other standards-based video endpoints and telepresence systems.

Today’s announcement extends that interoperability to provide the full telepresence experience when connecting with users of Polycom telepresence. This advanced telepresence interoperability, enabled through a TANDBERG Telepresence Server software upgrade, allows organizations to get the most out of their existing and future telepresence investments by enabling them to connect to a wider audience.

“Interoperability is now a critical business need and this announcement today shows our commitment in enabling open communities where people can collaborate naturally no matter how or where they are connecting,” said TANDBERG’s President for Asia Pacific (excluding China and Japan), Lars Rxnning, said.

“TANDBERG Telepresence systems are already interoperable with a broad range of third-party solutions. With high-definition multi-screen interoperability, TANDBERG delivers the best possible experience for customers connecting to their existing, or their partners’ telepresence systems,” added Rxnning.

“TANDBERG’s breakthrough in providing telepresence interoperability, coupled with BT’s industry leading One Source Managed Services, defines our shared focus of providing customers with high-impact communication, a simplified user experience, and maximum return on investment,” said Jeff Prestel, General Manager, BT Conferencing.

“With this interoperability first and our position as a global Certified Managed Services Provider for TANDBERG Total Service, BT and TANDBERG are poised to provide customers with a cost-effective, high quality immersive experience even when they may have different telepresence platforms. We’re allowing customers, suppliers and partners to communicate in ways never before possible, and creating business collaboration opportunities at a whole new level,” Prestel added.

“Everybody wants telepresence interoperability and now TANDBERG is providing it,” said Scott Allen, CEO, Iformata Communications, a global service provider.

“Instead of primarily providing a vertical support model for our customers, we will be able to seamlessly connect customers across previously insurmountable communication barriers. This will help us ensure that our customers receive the best possible return on their hardware investments,” Allen added. (ANI)

Indian link boosts S African Cipla Medpro profits

Johannesburg, April 3 (IANS) Exclusive access to a wide range of products from Cipla India helped boost revenues of pharmaceutical company Cipla Medpro South Africa by nearly 40 percent, the company reported.

With its revenues growing at 38.8 percent, Cipla Medpro again continued to grow faster than the total private market, but the company posted a loss of 15.6 million rands before interest and tax because of the huge costs of making its plant at Durban compliant with the Pharmaceutical Inspection Convention, it said on the Johannesburg Securities Exchange website.

Currently operating at 20 percent capacity, this highly sophisticated plant has an annual output capability of 3.5 billion tablets (with reserve) and may still take some time to see significant revenues being generated.

Growth was recorded across numerous categories, such as neuropsychiatry, asthma, cardiovascular, over the counter (OTC) and animal health.

This growth was attributed to product launches, exclusive access to Indian pharmaceutical giant Cipla India’s strong pipeline of products and dossiers, a strong and rapidly expanding OTC product portfolio, listings in mass market retailers, a large sales force and a continued aggressive marketing strategy.

Twenty five new products were launched during the year across all categories – skincare, colds and flu, and nutritional supplements, and further launches are scheduled for 2009.

Cipla said that its antidepressant, Lexamil, and its cardiovascular product, Cipla Perindopril, were each gaining market share of almost 40 percent in their markets, reflecting a trend of increased demand for these two stress-related drug types in the current global financial meltdown.

Cipla is also one of the leading generic anti-retroviral producers, having won a government contract last year. This will see the entry of supplies from the local plant, as well as from the Mumbai-based plant, Cipla India.

The pipeline from Cipla India remains strong, with the benefit of favourable prices and payment terms. Cipla Medpro currently has 155 dossiers awaiting registration, another 37 about to be submitted and a further 46 dossiers ordered from Cipla India for delivery over the next 12 months.

Cipla Vet, the companion animal veterinary products business, has recently launched the first generic of the world’s biggest selling tick and flea product, with the company projecting significant market share gains in this category during 2009.

After in-depth industry research and analysis, the new agricultural chemicals division, Cipla Agricare launched recently with a comprehensive range of 21 internationally SGA-certified pesticides. With another 12 products expected soon from Cipla India for local trials and registration and a further six ready for registration, it is envisaged that the targeted market share and revenues are attainable within approximately four seasons.